Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Bulletin du Cancer Année : 2017

The breakthrough of personalized medicine, new hopes and new challenges

Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie

Résumé

The development of personalized medicine in oncology is based on biomarkers that help select populations for more efficient and less toxic therapies. The onset of molecular biology led to new paradigms in drug development, with efficacy data reported in early clinical trials and accelerated approvals. Multiple clinical trials, including SHIVA, SAFIR-01 and MOSCATO-01, have been developed to evaluate the interest of treatment decision-making based on tumor molecular profiling, with the ambition to replace historical clinical and pathological classifications. Targeted molecular therapies have also drastically enhanced the prognosis of patients in several cancer subtypes, with increased use in the context of advanced palliative care. Breaking through those boundaries might lead to a true precision medicine in oncology, which implementation in clinical routine is now expected by patients and physicians.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-02370054 , version 1 (19-11-2019)

Identifiants

Citer

Ronan Flippot, Christophe Massard, Édouard Auclin, David Azria, Heloise Bourien, et al.. Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie. Bulletin du Cancer, 2017, 104 (9), pp.735-743. ⟨10.1016/j.bulcan.2017.07.003⟩. ⟨hal-02370054⟩
150 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More